Activin receptor: Difference between revisions
Jump to navigation
Jump to search
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load=' | <StructureSection load='3mtf' size='340' side='right' caption='Caption for this structure' scene=''> | ||
<ref>PMID:21638687</ref> to the rescue. | <ref>PMID:21638687</ref> to the rescue. | ||
== Function == | == Function == | ||
'''Activin receptors''' (Acvr) are integral to the activin and myostatin signalling pathway. Binding of activin to the Acvr on muscle cell membrane leads to enhanced muscle protein breakdown and debilitating loss of muscle mass and functional capacity<ref>PMID:23721881</ref>. | |||
== Disease == | == Disease == | ||
A mutation in Acrv1 exists in individuals with the rare developmental disorder fibrodysplasia ossificans progressiva<ref>PMID:28918311</ref>. | |||
== Relevance == | == Relevance == | ||
Increased activin/Acvr2 signalling links aging and heart failure pathobiology and that targeted inhibition of this catabolic pathway may form a therapeutic strategy for multiple forms of hear failure<ref>PMID:30842316</ref>. | |||
== Structural highlights == | == Structural highlights == | ||
| Line 19: | Line 25: | ||
{{#tree:id=OrganizedByTopic|openlevels=0| | {{#tree:id=OrganizedByTopic|openlevels=0| | ||
*Activin receptor type 1 or Activin receptor-like type 2 or Serine/threonine-protein kinase receptor R1 or ALK2 | *Activin receptor type 1 or Activin receptor-like type 2 or Serine/threonine-protein kinase receptor R1 or ALK2 or BMP type 1 receptor kinase | ||
**[[5oxg]] - hAcvr1 kinase domain 172-499 + inhibitor - human<br /> | **[[5oxg]] - hAcvr1 kinase domain 172-499 + inhibitor - human<br /> | ||
Revision as of 11:48, 6 May 2020
[1] to the rescue. FunctionActivin receptors (Acvr) are integral to the activin and myostatin signalling pathway. Binding of activin to the Acvr on muscle cell membrane leads to enhanced muscle protein breakdown and debilitating loss of muscle mass and functional capacity[2]. DiseaseA mutation in Acrv1 exists in individuals with the rare developmental disorder fibrodysplasia ossificans progressiva[3]. RelevanceIncreased activin/Acvr2 signalling links aging and heart failure pathobiology and that targeted inhibition of this catabolic pathway may form a therapeutic strategy for multiple forms of hear failure[4]. Structural highlights |
| ||||||||||
3D structures of activin receptor3D structures of activin receptor
Updated on 06-May-2020
ReferencesReferences
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
- ↑ Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013 Oct;45(10):2333-47. doi:, 10.1016/j.biocel.2013.05.019. Epub 2013 May 28. PMID:23721881 doi:http://dx.doi.org/10.1016/j.biocel.2013.05.019
- ↑ Williams E, Bullock AN. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone. 2017 Sep 12. pii: S8756-3282(17)30340-X. doi: 10.1016/j.bone.2017.09.004. PMID:28918311 doi:http://dx.doi.org/10.1016/j.bone.2017.09.004
- ↑ Roh JD, Hobson R, Chaudhari V, Quintero P, Yeri A, Benson M, Xiao C, Zlotoff D, Bezzerides V, Houstis N, Platt C, Damilano F, Lindman BR, Elmariah S, Biersmith M, Lee SJ, Seidman CE, Seidman JG, Gerszten RE, Lach-Trifilieff E, Glass DJ, Rosenzweig A. Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med. 2019 Mar 6;11(482). pii: 11/482/eaau8680. doi:, 10.1126/scitranslmed.aau8680. PMID:30842316 doi:http://dx.doi.org/10.1126/scitranslmed.aau8680